India Greenlights First Dengue Vaccine, Qdenga: A Major Step in Public Health Battle

India has officially approved its first-ever dengue vaccine, Qdenga, from Japanese pharmaceutical giant Takeda, marking a significant milestone in the country's fight against the rapidly spreading mosquito-borne disease. The Central Drugs Standard Control Organisation (CDSCO) and the Drug Controller General of India (DCGI) granted marketing authorisation for the Dengue Tetravalent Vaccine-Qdenga, which is designed to protect individuals aged 4 to 60 years against all four dengue virus serotypes without needing prior infection screening. This move is a game-changer for a nation that bears nearly one-third of the global dengue burden. Dengue has become a year-round threat in India, no longer just a monsoon-season problem, with cases dramatically rising and even spreading to colder, high-altitude regions. Unlike previous vaccine attempts like Dengvaxia, Qdenga offers a crucial advantage by not requiring pre-vaccination testing, simplifying its rollout and making it more accessible to eligible individuals. Takeda's global clinical trials, including a specific Phase III study in India, demonstrated strong efficacy, showing sustained protection against dengue infection and hospitalisation for up to seven years. While the exact pricing for Qdenga in India is yet to be announced, a manufacturing partnership with Hyderabad-based Biological E is in the works, aiming to produce up to 50 million doses annually, which could influence its eventual cost and public accessibility. The vaccine's two-dose regimen, administered three months apart via subcutaneous injection, will complement existing public health measures like vector control and surveillance. This approval opens a new chapter in India's public health strategy, offering a powerful new tool against a disease that places immense medical and economic strain on the country.